Fulgent Genetics Appoints Dr. Lawrence Weiss as Chief Medical Officer
May 06, 2021 at 11:00 am
Share
Fulgent Genetics, Inc. announced the appointment of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the Company’s Chief Executive Officer, Ming Hsieh. Dr. Weiss will be responsible for expanding Fulgent’s reach in molecular diagnostics and driving the advancement of the Company’s portfolio of oncologic testing solutions. Dr. Weiss brings extensive experience in medical and scientific leadership to Fulgent Genetics. Most recently, he was Chief Medical Officer at NeoGenomics where he oversaw the medical and the research and development teams. Prior to NeoGenomics, Dr. Weiss served as Laboratory Director for Clarient Diagnostic Services and as Chairman of the Department of Pathology and Director of Laboratories for City of Hope National Medical Center.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.